Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-06-14
2011-06-14
Tsang, Cecilia (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S011100
Reexamination Certificate
active
07960342
ABSTRACT:
SRIF peptide antagonists, which are selective for SSTR2 in contrast to the other cloned SRIF receptors and which bind with high affinity to the cloned human receptor SSTR2 but do not activate the receptor, have many useful functions. Because they do not bind with significant affinity to SSTR1, SSTR3, SSTR4 or SSTR5, their administration avoids potential undesirable side effects. Because they block the receptor function, they can be used therapeutically to block certain physiological effects which SSTR2 mediates. By incorporating radioiodine or the like in these SSTR2-selective SRIF antagonists, a labeled compound useful in drug-screening methods is provided. Alternatively, for use in therapy, highly radioactive moieties can be N-terminally coupled, complexed or chelated thereto.
REFERENCES:
patent: 4428942 (1984-01-01), Rivier et al.
patent: 5590656 (1997-01-01), O'Dorisio et al.
patent: 5837218 (1998-11-01), Peers et al.
patent: 5846934 (1998-12-01), Bass et al.
patent: 5925618 (1999-07-01), Baumbach et al.
patent: 6262229 (2001-07-01), Coy et al.
patent: 6579967 (2003-06-01), Rivier et al.
patent: 7019109 (2006-03-01), Rivier et al.
patent: 2002/0137676 (2002-09-01), Hsiang et al.
patent: 2004/0242842 (2004-12-01), Maecke et al.
patent: 2005/0070470 (2005-03-01), Coy et al.
patent: 2005/0245438 (2005-11-01), Rivier et al.
patent: 2006/0089299 (2006-04-01), Hsiang et al.
patent: 0 203 031 (1992-07-01), None
patent: WO97/11962 (1997-04-01), None
patent: WO-98/24807 (1998-06-01), None
patent: WO00/12111 (2000-03-01), None
patent: WO-01/44273 (2001-06-01), None
patent: WO-02/32932 (2002-04-01), None
patent: WO2004/082722 (2004-09-01), None
patent: WO-2008/048942 (2008-04-01), None
Hirst et al., “Structure-Activity Studies with Somatostatin: the Role of Tryptophan in Position 8”,Regulatory Peptides(1980), vol. 1, pp. 97-113.
Reubi et al., “Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting”,European Journal of Nuclear Medicine and Molecular Imaging(2003), vol. 30, No. 5, pp. 781-793.
Schottelius et al., “First 18F-Labeled Tracer Suitable for Routine Clinical Imaging of sst Receptor-Expressing Tumors Using Positron Emission Tomography”,Clinical Cancer Research(2004), vol. 10, pp. 3593-3606.
Yabe et al., “Synthesis and Biological Activity of Somatostatin Analogues modified at the Tryptophan Residue”,Chem. Pharm. Bull.(1978), vol. 26, No. 3, pp. 993-997.
International Search Report (PCT/US2009/040672) dated May 11, 2010.
Ginj,et al,“Radiolabeled Somatostatin Receptor Antagonists are Preferable to Agonists for in Vivo Peptide Receptor Targeting of Tumors,” Proceedings of the National Academy of Sciences of the United States of America,vol. 103,No. 44,Oct. 2006.
Lloyd, et al., “Activation of Somatostatin Receptor Subtype 2 Inhibits Acid Secretion in Rats,” American Journal of Physiology: Gastrointestinal and Liver Physiology, American Physiological Society, vol. 268, No. 1, Pt. 1, 1995, pp. G102-G106.
Murphy,et al.,“Octapeptide Analogs of Somatostatin Exhibiting Greatly Enhanced in Vito and in Vitro Inhibition of Growth Hormone Secretion in the Rat,” Biochemical and Biophysical Research Communications,Academic Press,San Diego,CA,vol. 132,No. 3,Nov. 15, 1985.
Erchegyi Judit
Maecke Helmut R.
Reubi Jean Claude
Rivier Jean E. F.
Foley & Lardner LLP.
Heard Thomas S
Lomprey Jeffrey R.
The Salk Institute for Biological Studies
Tsang Cecilia
LandOfFree
Receptor(SSTR2)-selective somatostatin antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Receptor(SSTR2)-selective somatostatin antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Receptor(SSTR2)-selective somatostatin antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2714694